SG11202108737RA - Combinations of binding moieties that bind egfr, her2 and her3. - Google Patents

Combinations of binding moieties that bind egfr, her2 and her3.

Info

Publication number
SG11202108737RA
SG11202108737RA SG11202108737RA SG11202108737RA SG11202108737RA SG 11202108737R A SG11202108737R A SG 11202108737RA SG 11202108737R A SG11202108737R A SG 11202108737RA SG 11202108737R A SG11202108737R A SG 11202108737RA SG 11202108737R A SG11202108737R A SG 11202108737RA
Authority
SG
Singapore
Prior art keywords
her3
her2
combinations
binding moieties
bind egfr
Prior art date
Application number
SG11202108737RA
Inventor
Cecilia Anna Wilhelmina Geuijen
Tristan Louis Jean Gallenne
Mark Throsby
Kruif Cornelis Adriaan De
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of SG11202108737RA publication Critical patent/SG11202108737RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202108737RA 2019-02-14 2020-02-13 Combinations of binding moieties that bind egfr, her2 and her3. SG11202108737RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19157302 2019-02-14
EP19178564 2019-06-05
PCT/NL2020/050081 WO2020167123A1 (en) 2019-02-14 2020-02-13 Combinations of binding moieties that bind egfr, her2 and her3.

Publications (1)

Publication Number Publication Date
SG11202108737RA true SG11202108737RA (en) 2021-09-29

Family

ID=69771003

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108737RA SG11202108737RA (en) 2019-02-14 2020-02-13 Combinations of binding moieties that bind egfr, her2 and her3.

Country Status (13)

Country Link
US (1) US20220127376A1 (en)
EP (1) EP3924384A1 (en)
JP (2) JP2022520649A (en)
KR (1) KR20210126703A (en)
AU (1) AU2020222749A1 (en)
BR (1) BR112021016094A2 (en)
CA (1) CA3130248A1 (en)
IL (1) IL285490A (en)
MA (1) MA54944A (en)
MX (1) MX2021009768A (en)
SG (1) SG11202108737RA (en)
TW (1) TW202045541A (en)
WO (1) WO2020167123A1 (en)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
AU2009263082C1 (en) 2008-06-27 2018-11-01 Merus N.V. Antibody producing non-human mammals
TWI461211B (en) 2009-03-20 2014-11-21 Genentech Inc Anti-her antibodies
EP2635604B1 (en) * 2010-11-01 2016-11-30 Symphogen A/S Pan-her antibody composition
ES2743399T3 (en) 2012-04-20 2020-02-19 Merus Nv Methods and means for the production of Ig-like heterodimeric molecules
AU2013255537B2 (en) * 2012-05-02 2018-02-15 Symphogen A/S Humanized pan-her antibody compositions
KR20150013188A (en) * 2012-05-24 2015-02-04 에프. 호프만-라 로슈 아게 Multispecific antibodies
WO2015130172A1 (en) 2014-02-28 2015-09-03 Merus B.V. Antibodies that bind egfr and erbb3
US11279770B2 (en) 2014-02-28 2022-03-22 Merus N.V. Antibody that binds ErbB-2 and ErbB-3
EP3126384B1 (en) * 2014-04-01 2020-12-02 Adimab, LLC Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
AU2015313811A1 (en) * 2014-09-08 2017-04-06 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI)

Also Published As

Publication number Publication date
BR112021016094A2 (en) 2021-10-26
MX2021009768A (en) 2021-09-08
CA3130248A1 (en) 2020-08-20
TW202045541A (en) 2020-12-16
US20220127376A1 (en) 2022-04-28
WO2020167123A1 (en) 2020-08-20
EP3924384A1 (en) 2021-12-22
KR20210126703A (en) 2021-10-20
MA54944A (en) 2021-12-22
JP2022520649A (en) 2022-03-31
IL285490A (en) 2021-09-30
JP2024023598A (en) 2024-02-21
AU2020222749A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
IL277398A (en) Pd-l1 binding affimers, and uses related thereto
IL272461A (en) Antibodies that bind egfr and cmet
IL279133A (en) Tumor microenvironment-activated drug-binder conjugates, and uses related thereto
PH12019502087A1 (en) Anti-par2 antibodies and uses thereof
SG11202106435QA (en) Treating gastric cancer using ttfields combined with xelox or folfox
IL286536A (en) Egfr x cd28 multispecific antibodies
MX2014014162A (en) Multispecific antibodies.
WO2011109298A3 (en) Therapeutic dll4 binding proteins
WO2016205427A3 (en) Binding proteins against vegf, pdgf, and/or their receptors
DK3582806T3 (en) PROTEINS THAT BIND HER2, NKG2D AND CD16
SG11202109545VA (en) Treatment employing anti-il-13r antibody or binding fragment thereof
PH12019500551A1 (en) Antibody specifically binding to il-17a and functional fragment thereof
PH12018501944A1 (en) Engineered immunoglobulins with altered fcrn binding
IL274121A (en) Bispecific antibodies binding alk-1 and bmpr-2
IL280656A (en) Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of use
EP3665200A4 (en) Her3 binding agents and uses thereof
IL285813A (en) Antigen binding proteins that bind bcma
IL286504A (en) Anti-cd73, anti-pd-l1 antibodies and chemotherapy for treating tumors
MX2017007747A (en) Antibodies for il-17c.
EA201992315A1 (en) COMPOSITIONS AND METHODS FOR TREATING LUNG CANCER
EP3947465A4 (en) Engineered variant antibodies that bind cd38
IL279325A (en) Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof
SG11202108737RA (en) Combinations of binding moieties that bind egfr, her2 and her3.
CL2020000442S1 (en) Binding tool.
GB201709379D0 (en) Humanised ADAMTS13 binding antibodies